チーム医療のための がんロコモハンドブック

出版社: 総合医学社
著者:
発行日: 2021-10-30
分野: 臨床医学:一般  >  癌/腫瘍一般
ISBN: 9784883787401
電子書籍版: 2021-10-30 (第1版第1刷)
書籍・雑誌
≪全国送料無料でお届け≫
取寄せ目安:8~14営業日

4,950 円(税込)

電子書籍
章別単位での購入はできません
ブラウザ、アプリ閲覧

4,950 円(税込)

商品紹介

がん患者が動ける・社会活動できることを目指す「がんロコモ」対策を、多職種によるチーム医療で行うための一冊。
がん医療・運動器障害の丁寧な解説で、がん患者の診療に関わるすべての医師・パラメディカルに必携。

目次

  • I .総論:がん患者の運動器管理の重要性
     1.ロコモティブシンドロームとは
     2.がんロコモとは

    II .がんロコモ治療に必要ながん医療の基礎知識
     1.がんの評価
     2.治療総論

    III .がんロコモ治療に必要な運動器障害の知識
     1.運動器の評価
     2.神経学的所見の評価
     3.ロコモティブシンドロームの評価
     4.骨粗鬆症の評価と治療(がん治療による骨粗鬆症を含む)
     5.運動器のリハビリテーション診療
     6.がん患者における鑑別すべき運動器疾患
     7.骨転移
     8.腫瘍随伴症候群
     9.がん患者における薬剤性末梢神経障害とリハビリテーション治療
     10.運動器障害・運動制限を起こす抗悪性腫瘍薬の副作用
     11.骨転移を起こしやすいがんとその治療

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

I. 総論 : がん患者の運動器管理の重要性

P.8 掲載の参考文献
1) 中村耕三:超高齢社会とロコモティブシンドローム. 日整会誌 82:1-2, 2008
2) 大江隆史:ロコモティブシンドロームの概念. 臨スポーツ医 27:1-6, 2010
3) Yoshimura N, Mukai S, Oka H et al:Prevalence of knee osteoarthritis, lumbar spondylosis and osteoporosis in Japanese men and women;the research on osteoarthritis/osteoposis against disability study. J Bone Miner Metab 27:620-628, 2009
4) Yoshimura N, Muraki S, Nakamura K et al:Epidemiology of the locomotive syndrome:The research on osteoarthritis/osteoporosis against disability study 2005-2015. Mod Rheumatol 27:1-7, 2017
P.14 掲載の参考文献
1) 中村耕三:超高齢社会とロコモティブシンドローム. 日整会誌 82:1-2, 2008
4) Sternheim A, Saidi K, Lochab J et al:Internal fixation of radiation-induced pathological fractures of the femur has a high rate of failure. Bone Joint J 95-B:1144-1148, 2013

II. がんロコモ治療に必要ながん医療の基礎知識

P.21 掲載の参考文献
1) Saubermann AJ, Lagasse RS:Prediction of rate and severity of adverse perioperative outcomes:"normal accidents" revisited. Mt Sinai J Med 79(1):46-55, 2012
2) West H, Jin JO:Performance status in patients with cancer. JAMA Oncology 1(7):998, 2015
3) Ohe Y, Yamamoto S, Suzuki K et al:Risk factors of treatment-related death in chemotherapy and thoracic radiotherapy for lung cancer. Eur J Cancer 37(1):54-63, 2001
4) Ando M, Ando Y, Hasegawa Y et al:Prognostic value of performance status assessed by patients themselves, nurses, and oncologists in advanced non-small cell lung cancer. British journal of cancer 85(11):1634-1639, 2001
5) Scott JM, Stene G, Edvardsen E et al:Performance status in cancer:not broken, but time for an upgrade? J Clin Oncol 38(25):2824-2829, 2020
P.28 掲載の参考文献
1) 全国がんセンター協議会「全がん協生存率調査」 http://www.zengankyo.ncc.go.jp/etc/(accessed 2021.3.18)
2) 国立がん研究センターがん情報サービス「最新がん統計」 https://ganjoho.jp/reg_stat/statistics/stat/summary.html(accessed 2021.3.18)
3) 厚生労働省 令和2年度版厚生労働白書-令和時代の社会保障と働き方を考える- https://www.mhlw.go.jp/stf/wp/hakusyo/kousei/19/index.html(accessed 2021.3.18)
4) 国立がん研究センターがん情報サービス「全国がん罹患モニタリング集計」 https://ganjoho.jp/reg_stat/statistics/brochure/monitoring.html(accessed 2021.3.18)
5) Wildiers H, Heeren P, Puts M et al:International Society of Geriatric Oncology consensus on geriatric assessment in older patients with cancer. J Clin Oncol 32(24):2595-2603, 2014
P.35 掲載の参考文献
1) International Union Against Cancer(UICC) committee on Clinical Stage Classification and Applied Statistics, Clinical Stage Classification and Presentation of Results, Malignant Tumours of Breast and Larynx. Paris, 1958
2) Brierley, JD, Gospodarowicz, MK, Wittekind C. (eds.):TNM Classification of Malignant Tumours, 8th ed. John Wiley & Sons, 2017
3) Brierley, JD, Gospodarowicz, MK, Wittekind C. (eds.)UICC日本委員会TNM委員会 訳:TNM 悪性腫瘍の分類 第8版(日本語版). 金原出版, 2017
4) 日本肺癌学会 編:臨床・病理 肺癌取扱い規約 第8版. 金原出版, 2017
5) 大腸癌研究会 編:大腸癌取扱い規約 第9版. 金原出版, 2017
P.42 掲載の参考文献
1) Specchia ML, Frisicale EM, Carini E et al:The impact of tumor board on cancer care:Evidence from an umbrella review. BMC Health Serv Res 20:73, 2020
2) Thenappan A, Halaweish I, Mody RJ et al:Review at a multidisciplinary tumor board impacts critical management decisions of pediatric patients with cancer. Pediatr Blood Cancer 64:254-258, 2017
3) 日本肺癌学会:肺癌診療ガイドライン2020年版
4) 日本脳腫瘍学会:脳腫瘍診療ガイドライン2016年版
5) 軟部腫瘍診療ガイドライン2020
6) 酒井良忠:その痛み, がんの痛みですか?. 臨整外 54:1011-1015, 2019
7) Bhattacharyya T, Iorio R, Healy W:Rate of risk factors for acute inpatient mortality after orthopaedic surgery. J Bone Joint Surg AM 84(4):562-572. 2002
8) 中村直樹:放射線治療医からみたがんロコモ. 臨整外 54:1017-1022, 2019
9) 篠田裕介:整形外科がキャンサーボードに参加すると. 臨整外 54:991-995, 2019
P.49 掲載の参考文献
1) Le DT, Uram JN, Wang H et al:PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med 372(26):2509-2520, 2015
2) Doebele RC, Drilon A, Paz-Ares L et al:Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours:integrated analysis of three phase 1-2 trials. Lancet Oncol 21(2):271-282, 2020
3) Kris MG, Johnson BE, Berry LD et al:Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs. JAMA 311(19):1998-2006, 2014
4) 固形がんの治療効果判定のための新ガイドライン(RECISTガイドライン)-改訂版version 1.1 -日本語訳JCOG版 ver.1.0
5) 日本癌治療学会:制吐薬適正使用ガイドライン2015年10月(第2版). 一部改訂版ver.2.2. 2018年10月
6) 日本臨床腫瘍学会 編:発熱性好中球減少症(FN)診療ガイドライン改訂第2版, 南江堂, 2017
7) 国立がん研究センター内科レジデント 編:がん診療レジデントマニュアル第7版. 医学書院, 2016
P.56 掲載の参考文献
1) 園田 茂:不動・廃用症候群. Jpn J Rehabil Med 52:265-271, 2015
2) 佐藤知香 他:安静臥床が及ぼす全身への影響と離床や運動負荷の効果について. Jpn J Rehabil Med 56:842-847, 2019
3) Fearon KCH, Ljunggvist O, Von Meyenfeldt M et al:Enhanced recovery after surgery:A consensus review of clinical care for patients undergoing colonic resection. Clinical Nutrition 24:466-477, 2005
4) 宮田 剛:ESSENSEとは何か -外科手術後の回復を促進するための4つのキーワード-. 外科と代謝 47:147-154, 2013
5) 井上順一郎, 小野 玲, 柏美由紀 他:食道癌患者における積極的な術前呼吸リハビリテーションと術後呼吸器合併症との関係. 理学療法学 38(3):201-206, 2011
6) 国立がん研究センターがん情報サービス「がん登録・統計」(全国がん登録) https://ganjoho.jp/reg_stat/statistics/dl/index.html#incidence
7) Cruz-Jentoft AJ, Bahat G, Bauer J et al:Sarcopenia:revised European consensus on definition and diagnosis. Age Ageing 48:16-31, 2019
8) 吉田貞夫:サルコペニア, フレイル患者の周術期感染症のリスクと栄養管理. 外科と代謝 53:97-103, 2019
P.63 掲載の参考文献
1) Spencer KL, van der Velden JM, Wong E et al:Systematic review of the role of stereotactic radiotherapy for bone metastases. J Natl Cancer Inst 111:1023-1032, 2019
3) Nguyen QN, Chun SG, Chow E et al:Single-fraction stereotactic vs conventional multifraction radiotherapy for pain relief in patients with predominantly nonspine bone metastases:A randomized phase 2 trial. JAMA Oncol 5:872-878, 2019
4) Fisher CG, DiPaola CP, Ryken TC et al:A novel classification system for spinal instability in neoplastic disease:an evidence-based approach and expert consensus from the Spine Oncology Study Group. Spine(Phila Pa 1976) 35:E1221-E1229, 2010
5) Palma DA, Olson R, Harrow S et al:Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers(SABR-COMET):a randomised, phase 2, open-label trial. Lancet 393:2051-2058, 2019
P.68 掲載の参考文献
1) International Association for the Study of Pain. IASP terminology. Pain terms. https://www.iasp-pain.org/terminology?navItemNumber=576#Pain(Accessed 1st February, 2021)
2) PDQ Supportive and Palliative Care Editorial Board. PDQ cancer pain. Bethesda, MD:National Cancer Institute. Updated September 12, 2018 https://www.cancer.gov/about-cancer/treatment/side-effects/pain/pain-hp-pdq (Accessed 30 November, 2018)
3) IASP Terminology. International Association for the Study of Pain. Merskey H, and Bogduk N. (Eds). Part III:Pain Terms, A Current List with Definitions and Notes on Usage. In:Classification of Chronic Pain, Second Edition, IASP Task Force on Taxonomy, IASP Press, pp209-214, 1994 https://www.iasppain.org/Education/Content.aspx?ItemNumber=1698&navItemNumber=576(Accessed 30 November, 2018)
4) Mehta A, Chan LS:Understanding of the concept of "total pain." A prerequisite for pain control. J Hosp Palliat Nurs 10:26-32, 2008
5) Haumann J, Joosten EA, Everdingen MH:Pain prevalence in cancer patients:status quo or opportunities for improvement? Curr Opin Support Palliat Care 11:99-104, 2017
6) Greco MT, Roberto A, Corli O et al:Quality of cancer pain management:an update of a systematic review of undertreatment of patients with cancer. J Clin Oncol 32:4149-4154, 2014
7) Deandrea S, Montanari M, Moja L et al:Prevalence of undertreatment in cancer pain. A review of published literature. Ann Oncol 19:1985-1991, 2008
8) van den Beuken-van Everdingen MH, Hochstenback LM, Joosten EA et al:Update on prevalence of pain in patients with cancer:systematic review and meta-analysis. J Pain Symptom Manage 51:1070-1090, 2016
9) Iwase S et al:Assessment of cancer-related fatigue, pain, and quality of life in cancer patients at palliative care team referral:A multicenter observational study(JORTC PAL-09) PLoS One 10(8):e0134022, 2015
10) Higginson IJ, Murtagh FE, Osborne TR:Epidemiology of pain in cancer. In:Hanna M, Zylicz Z, eds. Cancer Pain. London, Springer-Verlag, 5-24, 2013
11) Hiraga K, Mizuguchi T, Takeda F:The incidence of cancer pain and improvement of pain management in Japan. Postgrad Med J 67(Suppl 2):S14-S25, 1991
12) Leppert W, Zajaczkowska R, Wordliczek J et al:Pathophysiology and clinical characteristics of pain in most common locations in cancer patients. J Physiol Pharmacol 67:787-799, 2016
13) Wood S:Anatomy and physiology of pain. Nursing Times. September 18, 2008
14) Murray GM:Guest Editorial:referred pain. J Appl Oral Sci 17(6), 2009
15) Oosterling A, te Boveldt N, Verhagen C:Neuropathic pain components in patients with cancer:prevalence, treatment, and interference with daily activities. Pain Pract 16:413-421, 2016
16) Argoff CE, Dubin A, Pilitsis J:Pain Management Secrets. 4th Ed. Philadelphia, PA, Elsevier Inc, 2018
17) Flatters SJL, Dougherty PM, Colvin LA:Clinical and preclinical perspectives on Chemotherapy-Induced Peripheral Neuropathy(CIPN):a narrative review. Br J Anaesth 119(4):737-749, 2017
18) Ibrahim EY, Ehrlich BE:Prevention of chemotherapy-induced peripheral neuropathy:A review of recent findings. Crit Rev Oncol Hematol 145:102831, 2020
19) Portenoy RK, Ahmed E:Cancer pain syndromes. Hematol Oncol Clin North Am 32:371-386, 2018
20) Ishiki H, Kinkawa J, Watanabe A et al:Prevalence of myofascial pain syndrome in patients with incurable cancer. J Bodyw Mov Ther 22(2):328-332, 2018
P.75 掲載の参考文献
1) 日本緩和医療学会 編:がん疼痛の薬物療法に関するガイドライン2020年版. 100-105, 2020
2) 成田 年:NSAIDsならびにアセトアミノフェンの作用機序から考えるがん疼痛治療効果の有用性-薬剤選択の基準と使用の意義の再認識. 薬局 63(6):2292-2300, 2012
P.80 掲載の参考文献
1) WHO Guidelines for the pharmacological and radiotherapeutic management of cancer pain in adults and adolescents. 2019 https://www.who.int/ncds/management/palliative-care/cancer-pain-guidelines/en/(last accessed Feb 14, 2021)
2) 2020年版日本緩和医療学会 緩和医療ガイドライン作成委員会:がん疼痛の薬物療法に関するガイドライン. 金原出版, 2014
3) Tsukuura H, Miyazaki M, Morita T et al:Efficacy of prophylactic treatment for oxycodone-induced nausea and vomiting among patients with cancer pain(POINT):A randomized, placebo-controlled, double- blind trial. Oncologist 23(3):367-374, 2018
P.86 掲載の参考文献
1) Hattori S:Spinal analgesia and neurolysis. Textbook of Palliative Medicine and Supportive care, 2nd edition. 449-460;CRC press, Taylor & Farancis Group. edited by Bruera, Florida, USA, 2015
2) De Oliveira R, dos Reis MP, Prado WA:The effects of early or late neurolytic sympathetic plexus block on the management of abdominal or pelvic cancer pain. Pain 110:400-408, 2004
3) Plancarte R, De Leon-Casasola OA, el-Helay M et al:Neurolytic superior hypogastric plexus block for chronic pelvic pain associated with cancer. Reg Anesth Pain Med 22:562-568, 1997
4) Lordon SP:Interventional approach to cancer pain. Curr Pain Headache Rep 6(3):202-206, 2002
5) Dermot RF:Pain in malignant disease. Cancer pain:Management:Bonica's management of Pain, third edition;659-703:Lippincott Williams & Wilkins, Philadelphia, USA, 2001
6) Turnbull DK, Shepherd DB:Post-dural puncture headache:pathogenesis, prevention and treatment. Br J Anaesth. 91(5):718-729. Review, 2003
P.93 掲載の参考文献
1) 辻 哲也:悪性腫瘍(がん). "現代リハビリテーション医学改訂第3版"千野直一 編. 金原出版, 493-504, 2009
2) 辻 哲也. がんに対するリハビリテーション医療の意義. "リハビリテーション医学・医療コアテキスト"日本リハビリテーション医学会 監. 医学書院, 248-251, 2018
3) 宮田知恵子:緩和ケアとがんのリハビリテーション診療. MB Medical Rehabilitation 247:1-8, 2020
4) Dietz JH:Rehabilitation of the cancer patient. Med Clin North Am 53:607-624, 1969
5) 日本リハビリテーション医学会 がんのリハビリテーション診療ガイドライン改訂委員会 編:がんのリハビリテーション診療ガイドライン第2版. 金原出版, 2019
P.101 掲載の参考文献
1) Fialka-Moser V, Crevenna R, Korpan M et al:Cancer rehabilitation:particularly with aspects on physical impairments. J Rehabil Med 35:153-162, 2003
2) 辻 哲也:がん. "リハビリテーション医学・医療コアテキスト"久保俊一 総編. 医学書院, 248-258, 2018
3) Ganz JS:Facilitating staff-patient interaction in rehabilitation. Rehabilitation Psychology, Caplan B(ed). An Aspen Publication, 185-218, 1987
4) Maltoni M, Nanni O, Pirovano M et al:Successful validation of the palliative prognostic score in terminally ill cancer patients. Italian Multicenter Study Group on Palliative Care. J Pain Symptom Manage 17(4):240-247, 1999
5) Morita T, Tsunoda J, Inoue S et al:The palliative prognostic index:a scoring system for survival prediction of terminally ill cancer patients. Support Care Cancer 7:128-133, 1999
6) Buccheri G, Ferrigno D, Tamburini M:Karnofsky and ECOG performance status scoring in lung cancer:a prospective, longitudinal study of 536 patients from a single institution. Eur J Cancer 32:1135-1141, 1996
7) Ando M, Ando Y, Hasegawa Y et al:Prognostic value of performance status assessed by patients themselves, nurses, and oncologists in advanced non-small cell lung cancer. Br J Cancer 85:1634-1639, 2001
8) Miyata C, Tsuji T, Tanuma A et al:Cancer functional assessment set:a new tool for functional evaluation in cancer. Am J Phys Med Rehabil 93(8):656-664, 2014
9) JCOG 日本臨床腫瘍研究グループホームページ:http://www.jcog.jp/doctor/tool/CTCAEv5.0J_20180915_miekeshi_v21_1.pdf(2021年2月10日閲覧)
10) 宮越浩一:リスク管理総論. "がん患者のリハビリテーション リスク管理とゴール設定"宮越浩一 編. メジカルビュー社, 68-77, 2013
11) 辻 哲也:がんのリハビリテーションの概要. "がんのリハビリテーションマニュアル"辻 哲也 編. 医学書院, 23-37, 2011
12) 水落和也:悪性腫瘍のリハビリテーション. リハ医学 38(1):46-57, 2001
13) Campbell KC, Winters-Stone KM, Wiskemann J et al:Exercise guidelines for cancer survivors:consensus statement from international multidisciplinary roundtable. Med Sci Sports Exerc 51(11):2375-2390, 2019
P.110 掲載の参考文献
1) 日本リハビリテーション医学会 編:がんのリハビリテーション診療ガイドライン 第2版. 金原出版, 2019
P.114 掲載の参考文献
1) Iwase S, Kawaguchi T, Tokoro A et al:Assessment of cancer-related fatigue, pain, and quality of life in cancer patients at palliative care team referral:A multicenter observational study(JORTC PAL-09). PLoS One 10(8):e0134022, 2015
2) Ishiki H, Kinkawa J, Watanabe A et al:Prevalence of myofascial pain syndrome in patients with incurable cancer. J Bodyw Mov Ther 22(2):328-332, 2018
3) Roldan CJ:Myofascial pain syndromes in the emergency department:What are we missing? The Journal of Emergency Medicine 49(6):1004-1010, 2015
P.120 掲載の参考文献
1) 厚生労働省:事業場における治療と仕事の両立支援のためのガイドライン. 令和2年3月改訂版.
2) 厚生労働省:仕事と治療の両立支援. がん患者・経験者の両立支援の推進について. https://www.mhlw.go.jp/stf/seisakunitsuite/bunya/kenkou_iryou/kenkou/gan/gan_byoin_00008.html
3) 第3期がん対策推進基本計画(平成30年3月9日閣議決定) https://www.mhlw.go.jp/file/05-Shingikai-10901000-Kenkoukyoku-Soumuka/0000208600.pdf
4) 厚生労働省保険局医療課:令和2年度診療報酬改定の概要(外来医療・かかりつけ機能). https://www.mhlw.go.jp/content/12400000/000605491.pdf
5) 「がん専門相談員のための学習の手引き~実践に役立つエッセンス~」改訂第3版. https://ganjoho.jp/data/hospital/consultation/files/gakushu_guide03.pdf
6) 阿部哲士:がんロコモの展望. 整形外科医に知ってほしい「がん相談支援センター」. 整・災外 62:883-886, 2019
7) 阿部哲士:就労支援とがんロコモ対策. Bone Joint Nerve 10:431-435, 2020
8) 森岡秀夫, 河野博隆 編著:がん患者の運動器疾患の診かた-新たなアプローチ「がんロコモ」. 中外医学社, 2019
9) 東京都福祉保健局:相談員向けがん患者就労支援研修テキスト(第3版). https://www.fukushihoken.metro.tokyo.lg.jp/iryo/iryo_hoken/gan_portal/staff_iryou/soudan_kesyu.files/kensyu_text.pdf
P.126 掲載の参考文献
1) 緒方直史:がんロコモの概念と意義-がんロコモによるがん患者の運動機能維持-. Jpn J Rehabil Med 57:284-288, 2020
2) Rando TA:Grief:Dying, and death:Clinical interventions for caregivers. Research Pr Pub. 1984
3) Hack TF, Chochinov HM, Hassard T et al:Defining dignity in terminally ill cancer patients:a factor-analytic approach. Psychooncology 13:700-708, 2004
4) 緒方直史:がんロコモの概念と意義-がんロコモによるがん患者の運動機能維持-. Jpn J Rehabil Med 57:284-288, 2020
6) 森田達也 他:終末期がん患者の霊的・実存的苦痛に対するケア-系統的レビューに基づく統合化. 緩和医療学 3(4):80-92, 2001
7) Mitchell AJ, Chan M, Bhatti H et al:Prevalence of depression, anxiety, and adjustment disorder in oncological, haematological, and palliative-care settings:a meta-analysis of 94 interview-based studies. Lancet Oncol 12:160, 2011
8) J. ウィリアム・ウォーデン(山本 力, 上地雄一郎, 桑原晴子 他訳):グリーフカウンセリング-悲しみを癒すためのハンドブック. 誠信書房, 2011
9) Diez JH:Rehabilitation of the cancer patients. Med Clin North Am 53:607-624, 1969
10) 栗原幸江:精神心理的問題(サイコオンコロジー). "癌のリハビリテーション"辻 哲也, 里宇明元, 木村彰男 編. 金原出版, p415, 2006
P.134 掲載の参考文献
1) 国立がん研究センター がん情報サービス 最新がん統計4. 生存率 https://ganjoho.jp/reg_stat/statistics/stat/summary.html(2021年2月8日アクセス)
2) 辻 哲也, 日本がん看護学会 監, 矢ヶ崎香 編:がん看護実践ガイド. サバイバーを支える看護師が行なうがんリハビリテーション. 第1章 サバイバーへのがんリハビリテーションの基本, 1. がんリハビリテーションの概要. 第1版, 医学書院, 2-9, 2016
3) Orem DE(小野寺杜紀 訳):オレム看護論. 第4版, 医学書院, 26, 2005

III. がんロコモ治療に必要な運動器障害の知識

P.143 掲載の参考文献
1) 足立誠司, 安部睦美:痛みの包括的評価. 日本緩和医療学会緩和医療ガイドライン委員会 編;がん疼痛の薬物療法に関するガイドライン(2014年版). 金原出版, 29-35, 2014
2) 米本恭三, 近藤 徹, 石神重信:関節可動域表示ならびに測定法(平成7年4月改訂). リハビリテーション医学 32:207-217, 1995
3) Avers D, Brown M(津山直一, 中村耕三 訳):新・徒手筋力検査法・原著第10版. 協同医書出版社, 2020
4) 津田英一:評価法の使い方・骨関節疾患. 総合リハビリテーション 49:395-399, 2021
5) Shumway-Cook A, Brauer S, Woollacott M:Predicting the probability for falls in community-dwelling older adults using the Timed Up & Go Test. Phys Ther 80:896-903, 2000
7) Yoshimura N, Muraki S, Oka H et al:Association between new indices in the locomotive syndrome risk test and decline in mobility:third survey of the ROAD study. J Orthop Sci 20:896-905, 2015
P.151 掲載の参考文献
1) 下津浦宏之, 井上聖啓:デルマトーム図. 脊髄外科 26:147-161, 2012
2) 廣瀬源二郎:Barre 試験とMingazzini 試験-Mingazzini 原著の重要性-. 臨神経 55:455-457, 2015
3) 小野哲郎:圧迫脊髄症の臨床と病理. 日整会誌 60:103-118, 1986
4) 森本忠嗣:Straight Leg Rising(SLRテスト)の定義の文献的検討. 日腰痛会誌 14:96-1012, 2008
5) Goddard MD, Reid JD:Movements induced by straight leg raising in the lumbo -sacral roots, nerves and plexus, and in the intrapelvic section of the sciatic nerve. J Neurol Neurosurg Psychiatry 28:12-18, 1965
P.156 掲載の参考文献
1) 日本整形外科学会:ロコモパンフレット2020年度版 https://locomo-joa.jp/check/pdf/locomo_pf2020.pdf
2) 村永信吾:立ち上がり動作を用いた下肢筋力評価とその臨床応用. 昭和医学会誌 61:362-367, 2001
3) 村永信吾, 平野清孝:2ステップテストを用いた簡便な歩行能力推定法の開発. 昭和医学会誌 63:301-308, 2003
P.166 掲載の参考文献
1) 日本骨粗鬆症学会 編:骨粗鬆症の予防と治療ガイドライン2015年版. ライフサイエンス出版, 2015
2) 日本骨粗鬆症学会 編:生活習慣病骨折リスクに関する診療ガイド2019年版. ライフサイエンス出版, 2019
3) Kimura T, Koike Y, Saito M et al:Short-term impact of androgen deprivation therapy on bone strength in castration-sensitive prostate cancer. Int J Urol 10:980-984, 2019
4) Wang A, Obertova Z, Brown C et al:Risk of fracture in men with prostate cancer on androgen deprivation therapy:a population-based cohort study in New Zealand. BMC Cancer 215:837, 2015
5) Colzani E, Clements M, Johansson ALV et al:Risk of hospitalisation and death due to bone fractures after breast cancer:a registry-based cohort study. Br J Cancer 115:1400-1407, 2016
6) Fukumoto S, Soen S, Taguchi T et al:Management manual for cancer treatment-induced bone loss(CTIBL):Position statement of JSBMR. J Bone Miner Metab 38:141-144, 2020
7) Saito M, Marumo K:Collagen cross-links as a determinant of bone quality:a possible explanation for bone fragility in aging, osteoporosis, and diabetes mellitus. Osteoporos Int(REVIEW) 21:195-214, 2010
8) Saito M, Marumo K:Effects of collagen crosslinking on bone material properties in health and disease. Calcif Tissue Int(Review) 97:242-261, 2015
9) Saito M, Fujii K, Soshi S et al:Reductions in degree of mineralization and enzymatic collagen cross-links and increases in glycation induced pentosidine in the femoral neck cortex in cases of femoral neck fracture. Osteoporos Int 17:986-995, 2006
10) Shiraki M, Kuroda T, Saito M et al:Urinary pentosidine and plasma homocysteine levels at baseline predict future fractures in osteoporosis under bisphosphonate treatment. J Bone Miner Metab 29:62-70, 2011, 2011
11) Saito M, Mori S, Mashiba T et al:Collagen maturity, glycation induced-pentosidine, and mineralization are increased following 3-year treatment with incadronate in dogs. Osteoporos Int 19:1343-1354, 2008
12) Mashiba T, Saito M, Yamagami Y et al:Effects of suppressed bone remodeling by minodronic acid and alendronate on bone mass, microdamage accumulation, collagen crosslinks and bone mechanical properties in the lumbar vertebra of ovariectomized cynomolgus monkeys. Bone 97:184-191, 2017
13) Sakai S, Takeda S, Sugimoto M et al:Treatment with the combination of ibandronate plus eldecalcitol has a synergistic effect on inhibition of bone resorption without suppressing bone formation in ovariectomized rats. Bone 81:449-458, 2015
15) Kimura S, Saito M, Kida Y et al:Effects of raloxifene and alendronate on non-enzymatic collagen cross-links and bone strength in ovariectomized rabbits in sequential treatments after daily human parathyroid hormone(1-34) administration. Osteoporos Int 28:1109-1119, 2016
16) Saito M, Kida Y, Nishizawa T et al:Effects of 18-month treatment with bazedoxifene on enzymatic immature and mature cross-links and non-enzymatic advanced glycation end products, mineralization, and trabecular microarchitecture of vertebra in ovariectomized monkeys. Bone 81:573-580, 2015
17) Delmas PD, Genant HK, Crans GG:Severity of prevalent vertebral fractures and the risk of subsequent vertebral and nonvertebral fractures:results from the MORE trial. Bone 33:522-532, 2003
18) Saito M, Grynpas MD, Burr DB et al:Treatment with eldecalcitol positively affects mineralization, microdamage, and collagen crosslinks in primate bone. Bone 73:8-15, 2015
P.176 掲載の参考文献
1) Seo DI, Kim E, Fahs CA et al:Reliability of the one-repetition maximum test based on muscle group and gender. J Sports Sci Med 11:221-225, 2012
2) Pedersen BK:Role of myokines in exercise and metabolism. J Appl Physiol 103:1093-1098, 2007
3) Gots-Neuman K(月城慶一 他訳):観察による歩行分析. 医学書院, 2005
4) 村永伸吾 他:高齢者の運動機能(健康増進歩行には高度のバランス機能が要求されるので, 平行棒内歩行, 松葉杖歩行, 杖歩行, さらに独歩訓練へと進めるのが一般的である)と理学療法. 理学療法ジャーナル 43:861-868, 2009
P.188 掲載の参考文献
1) 高木辰哉:がん診療医に向けたがんロコモのマネジメント. Bone Joint Nerve 10:385-390, 2020
2) 植野映子:脊椎腫瘍と他の脊椎疾患-画像所見. 脊椎転移パーフェクト診療. 高木辰哉 編. 南江堂, 26-33, 2020
3) 高木辰哉:がんロコモに対する横断的診療体制. Jpn J Rehabili Med 57:318-323, 2020
P.197 掲載の参考文献
1) 厚生労働省. 平成28年 国民生活基礎調査の概況. http://www.mhlw.go.jp/toukei/saikin/hw/k-tyosa/k-tyosa16/index.html
2) Yoshimura N et al:Cohort Profile:Research on Osteoarthritis/osteoporosis Against Disability(ROAD) study. Int J Epidemiol 39:988-995, 2010
3) Muraki S et al:Prevalence of radiographic knee osteoarthritis and its association with knee pain in the elderly of Japanese population based cohorts:the ROAD study. Osteoarthritis Cartitage 17:1137-1143, 2009
4) Kellgren JH et al:Radiological assessment of osteo-arthrosis. Ann Rheum Dis 16:494-502, 1957
5) Emmanuel K et al:Quantitative measures of meniscus extrusion predict incident radiographic knee osteoarthritis-data from the Osteoarthritis Initiative. Osteoarthritis Cartilage 24:262-269, 2016
6) Welsch GH et al:T2 and T2* Mapping. Curr Radiol Rep 2:60, 2014
7) Bannuru R.R et al:OARSI guidelines for the non-surgical management of knee, hip, and polyarticular osteoarthritis. Osteoarthritis Cartilage, 27:1578-1589, 2019
8) 日本整形外科学会変形性膝関節症診療ガイドライン策定委員会:変形性膝関節症の管理に関するOARSIによる勧告OARSIによるエビデンスに基づくエキスパートコンセンサスガイドライン. 日本整形外科学会, 2012
9) Brosseau L et al:The Ottawa panel clinical practice guidelines for the management of knee osteoarthritis. Part two:strengthening exercise programs. Clin Rehabil 31:596-611, 2017
10) Munukka M et al:Efficacy of progressive aquatic resistance training for tibiofemoral cartilage in postmenopausal women with mild knee osteoarthritis:a randomised controlled trial. Osteoarthritis Cartilage, 24:1708-1717, 2016
11) lshijima M et al:Intra-articular hyaluronic acid injection versus oral non-steroidal anti-inflammatory drug for the treatment of knee osteoarthritis:a multi-center, randomized, open-label, non-inferiority trial. Arthritis Res Ther 16:R18, 2014
12) 秋月 章:変形性関節症に対する関節温存療法 変形性膝関節症uniarthroplasty-人工膝単穎置換術. 関節外科 22:755-759, 2003
13) 石島旨章 他:変形性膝関節症の早期における半月板変性の機序. 整形・災害外科 63:519-529, 2020
14) 久保田光昭 他:変形性関節症 4. 骨切り術. 最新医学 別冊 診断と治療のABC 122:183-191, 2017
15) 石島旨章 他:変形性膝関節症における慢性疼痛. 日本臨牀 77:2027-2034, 2019
16) Peterfy CG et al:Whole-Organ Magnetic Resonance Imaging Score(WORMS) of the knee in osteoarthritis. Osteoarthritis Cartilage 12:177-190, 2004
17) Emmanuel K et al:Quantitative measures of meniscus extrusion predict incident radiographic knee osteoarthritis-data from the Osteoarthritis Initiative. Osteoarthritis Cartilage 24:262-269, 2016
P.206 掲載の参考文献
1) Ishimoto Y, Yoshimura N, Muraki S et al:Prevalence of symptomatic lumbar spinal stenosis and its association with physical performance in a population-based cohort in Japan:the Wakayama Spine Study. Osteoarthritis Cartilage 20:1103-1108, 2012
2) Conrad BP, Shokat MS, Abbasi AZ et al:Associations of self-report measures with gait, range of motion and proprioception in patients with lumbar spinal stenosis. Gait Posture 38(4):987-992, 2013
3) Suda Y, Saitou M, Shibasaki K et al:Gait analysis of patients with neurogenic intermittent claudication. Spine(Phila Pa 1976) 27(22):2509-2513, 2002
4) Fujita N, Sakurai A, Miyamoto A et al:Lumbar spinal canal stenosis leads to locomotive syndrome in elderly patients. J Orthop Sci 24:19-23, 2019
5) Fujita N, Michikawa T, Miyamoto A et al:Lumbar spinal surgery improves locomotive syndrome in elderly patients with lumbar spinal canal stenosis:A multicenter prospective study. J Orthop Sci 25(2):213-218, 2020
6) 日本整形外科学会・日本脊椎脊髄病学会 監:腰部脊柱管狭窄症診療ガイドライン2011. 南江堂, 2011
P.214 掲載の参考文献
1) 中島亜矢子 他:最新関節リウマチ学-寛解・治癒を目指した研究と最新治療-. 関節リウマチの予後因子. 関節リウマチにおける生命予後規定因子. 日本臨牀72(増刊3 最新関節リウマチ学), 673-676, 2014
2) 佐浦隆一 他:膠原病および類縁疾患のリハビリテーション医学・医療. 関節リウマチのリハビリテーション医学・医療. Jap J Rehabil Med 57:693-698, 2020
3) 箱田雅之 他:我が国における痛風患者数の今後の動向について. 痛風と尿酸・核酸 44:33-39, 2020
4) 益田郁子:結晶沈着性関節炎再訪. 痛風以外の結晶沈着性関節炎. CPP結晶沈着症の進歩. 高尿酸血症と痛風 27:39-44, 2019
5) Fuchs HA et al:Evidence of significant radiographic damage in rheumatoid arthritis within the first 2 years of disease. J Rheumatol 16:585-591, 1989
6) 針谷正祥:関節リウマチ(RA). 診断と治療の進歩III. 診断 1. ACR/EULARによる関節リウマチの2010新分類基準. 日内会誌 101:2851-2859, 2012
7) 川人 豊:ACR/EULAR 新寛解基準の意図するものと問題点. 臨床リウマチ 24:102-105, 2012
P.225 掲載の参考文献
1) 日本臨床腫瘍学会 編:骨転移診療ガイドライン. 南江堂, 2015
2) 森脇昭介, 万代光一, 山上啓太郎:癌の骨髄転移の病理形態と問題点. 病理と臨床 17:28-34, 1999
3) Yang HL, LiuT, Wang XM et al:Diagnosis of bone metastases:a meta-analysis comparing(18)FDG-PET, CT, MRI and bone scintigraphy. Eur Radiol 21:2604-2617, 2011
4) 中西克之, 酒井美緒, 前田 登 他:MRI による骨転移のスクリーニング. 臨床画像 36:865-872, 2020
5) 森岡秀夫, 西本和正, 堀内圭輔 他:骨転移に対する手術および骨修飾薬を用いた薬物療法. 臨床外科70:1493-1499, 2015
6) Tokuhashi Y, Uei H, Oshima M et al:Scoring system for prediction of metastatic spine tumor prognosis. World J Orthop 5:2186-2191, 2014
9) Mirels H:Metastatic disease in long bones:a proposed scoring system for diagnosing impending pathologic fractures. Clin Orthop 249:256-264, 1989
10) Chow E, Zeng L, Salvo N et al:Update on the systematic review of palliative radiotherapy trials for bone metastases. Clin Oncol 24:112-124, 2012
11) Steenland E, Leer J, van Houwelingen H et al:The effect of a single fraction compared to multiple fractions on painful bone metastases:a global analysis of the Dutch Bone Metastasis Study. Radiother Oncol 52:101-109, 1999
12) Henry DH, Costa L, Goldwasser F et al:Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer(excluding breast and prostate cancer) or multiple myeloma. J Clin Oncol 29:1125-1132, 2011
13) Stopeck AT, Lipton A, Body JJ et al:Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer:a randomized, double-blind study. J Clin Oncol 28:5132-5139, 2010
14) 森岡秀夫:骨転移診療の新しい流れ. 日整会誌87:S1089, 2013
15) 眞鍋 淳:がん骨転移に対する集学的治療-骨転移Cancer Board とBone Management. 癌の臨床58:43-50, 2012
P.236 掲載の参考文献
1) Solberg A, Bremnes RM:Metastatic spinal cord compression:diagnostic delay, treatment, and outcome. Anticancer Res 19:677-684, 1999
2) Coleman RE:Skeletal complications of malignancy. Cancer 80(8 Suppl):1588-1594, 1997
3) Falk S, Dickenson AH:Pain and nociception:mechanisms of cancer-induced bone pain. J Clin Oncol 32(16):1647-1654, 2014
4) 中田英二, 杉原進介, 菅原敬文 他:脊椎転移の早期診断・早期治療による麻痺予防とRT の治療成績. 整外最小侵襲誌 84:29-41, 2017
5) 中田英二, 杉原進介, 尾崎敏文:骨転移診療システム-脊椎転移による麻痺や廃用症候群予防を目的とした取り組み. 関節外科 35:38-51, 2016
6) 中田英二, 杉原進介, 尾崎敏文:脊椎転移による麻痺を予防する取り組み. 腫瘍内科 18:362-370, 2016
7) 日本臨床腫瘍学会:骨転移ガイドライン. p13, 南江堂, 2015
8) 腰痛診療ガイドライン策定委員会:腰痛患者が初診した場合に必要とされる診断の手順は. 腰痛診療ガイドライン策定委員会. 腰痛診療ガイドライン. 26-29, 南江堂, 2012
9) Mirels H:Metastatic disease in long bones. A proposed scoring system for diagnosing impending pathologic fractures. Clin Orthop Relat Res(249):256-264, 1989
10) Van der Linden YM, Dijkstra PD, Kroon HM et al:Comparative analysis of risk factors for pathological fracture with femoral metastases. .J Bone Joint Surg Br 86(4):566-573, 2004
11) Tatar Z, Soubrier M, Dillies AF et al:Assessment of the risk factors for impending fractures following radiotherapy for long bone metastases using CT scan-based virtual simulation:a retrospective study. Radiat Oncol 9:227, 2014
12) Fisher CG, DiPaola CP, Ryken TC et al:A novel classification system for spinal instability in neoplastic disease:an evidence-based approach and expert consensus from the Spine Oncology Study Group. Spine(Phila Pa 1976) 35(22):E1221-E1229, 2010
13) Nakata E, Sugihara S, Kataoka M et al:Early response assessment of palliative conventional radiotherapy for painful uncomplicated vertebral bone metastases. J Orthop Sci 23(6):912-917, 2018
14) Nakata E, Sugihara S, Kataoka M et al:Early response assessment of re-ossification after palliative conventional radiotherapy for vertebral bone metastases. J Orthop Sci 24(2):332-336, 2019
15) 中田英二, 杉原進介, 尾崎敏文:麻痺の無い脊椎の骨関連事象(SRE)に対するRTの治療成績. 整外と災外 66(4):921-925, 2017
16) 菊内祐人, 中田英二, 杉原進介 他:骨転移のリハビリテーション. 作療ジャーナル 48(4):293-297, 2014
17) Nakata E, Sugihara S, Sugawara Y et al:Multidisciplinary treatment system for bone metastases for early diagnosis, treatment and prevention of malignant spinal cord compression. Oncol Lett 19(4):3137-3144, 2020
P.249 掲載の参考文献
1) Yamaguchi T:Intertrabecular vertebral metastases:metastases only detectable on MR imaging. Semin Musculoskelet Radiol 5:171-175, 2001
2) Takahara T, Imai Y, Yamashita T et al:Diffusion weighted whole body imaging with background body signal suppression(DWIBS):technical improvement using free breathing, STIR and high resolution 3D display. Radiat Med 22:275-282, 2004
3) Shigematsu Y, Hirai T, Kawanaka K et al:Distinguishing imaging features between spinal hyperplastic hematopoietic bone marrow and bone metastasis. AJNR Am J Neuroradiol 35:2013-2020, 2014
4) Lalam R, Cassar-Pullicino VN, McClure J et al:Entrapped intralesional marrow:a hitherto undescribed imaging feature of benign notochordal cell tumour. Skeletal Radiol 41:725-731, 2012
P.259 掲載の参考文献
1) Katagiri H, Okada R, Takagi T et al:New prognostic factors and scoring system for patients with skeletal metastasis Cancer Med 3(5):1359-1367, 2014
2) Nakamura N, Shikama N, Wada H et al:Patterns of practice in palliative radiotherapy for painful bone metastases:a survey in Japan.;Japanese Radiation Oncology Study Group Working Subgroup of Palliative Radiotherapy. Int J Radiat Oncol Biol Phys 83(1):e117-e120, 2012
3) Mizumoto M, Harada H, Asakura H et al:Radiotherapy for patients with metastases to the spinal column:a review of 603 patients at Shizuoka Cancer Center Hospital. Int J Radiat Oncol Biol Phys 79(1):208-213, 2011
5) Shimoyama T, Katagiri H, Harada H et al:Fracture after radiation therapy for femoral metastasis:incidence, timing and clinical features. J Radiat Res 58(5):661-668, 2017
6) Tanaka A, Katagiri H, Murata H et al:Surgery for femoral metastases. Bone Joint J 102-B(3):285-292, 2020
7) Katagiri H, Takahashi M, Inagaki J et al:Clinical results of nonsurgical treatment for spinal metastases. Int J Radiat Oncol Biol Phys 42(5):1127-1132, 1998
8) Patchell RA, Tibbs PA, Regine WF et al:Direct decompressive surgical resection in the treatment of spinal cord compression caused by metastatic cancer:a randomised trial. Lancet 366(9486):643-648, 2005
P.266 掲載の参考文献
2) Green JR, Muller K, Jaeggi KA:Preclinical pharmacology of CGP 42'446, a new, potent, heterocyclic bisphosphonate compound. J Bone Miner Res 9:745-751, 1994
3) Kohno N, Aogi K, Minami H et al:Zoledronic acid significantly reduces skeletal complications compared with placebo in Japanese women with bone metastases from breast cancer:a randomized, placebo-controlled trial. J Clin Oncol 23:3314-3321, 2005
4) Rosen LS, Gordon D, Kaminski M et al:Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma:a randomized, double-blind, multicenter, comparative trial. Cancer 98:1735-1744, 2003
5) Saad F, Gleason DM, Murray R et al:Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J Natl Cancer Inst 96:879-882, 2004
6) Rosen LS, Gordon D, Tchekmedyian S et al:Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors:a phase III, double-blind, randomized trial--the Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group. J Clin Oncol 21:3150-3157, 2003
8) Morgan GJ, Davies FE, Gregory WM et al:First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma(MRC Myeloma IX):a randomised controlled trial. Lancet 376:1989-1999, 2010
9) Lipton A, Fizazi K, Stopeck AT et al:Superiority of denosumab to zoledronic acid for prevention of skeletal-related events:A combined analysis of 3 pivotal, randomised, phase 3 trials. Eur J Cancer 48:3082-3092, 2012
10) Coleman R, Finkelstein DM, Barrios C et al:Adjuvant denosumab in early breast cancer(D-CARE):an international, multicentre, randomised, controlled, phase 3 trial. Lancet Oncol 21(1):60-72, 2020
11) Dalle Carbonare L, Zanatta M, Gasparetto A et al:Safety and tolerability of zoledronic acid and other bisphosphonates in osteoporosis management. Drug Healthc Patient Saf 2:121-137, 2010
12) Hwang JS, Chin LS, Chen JF et al:The effects of intravenous zoledronic acid in Chinese women with postmenopausal osteoporosis. J Bone Miner Metab 29:328-333, 2011
13) Watts NB, Diab DL:Long-term use of bisphosphonates in osteoporosis. J Clin Endocrinol Metab 95:1555-1565, 2010
14) Silverman SL, Kriegman A, Goncalves J et al:Effect of acetaminophen and fluvastatin on post-dose symptoms following infusion of zoledronic acid. Osteoporos Int 22:2337-2345, 2011
15) Saad F, Brown JE, Van Poznak C et al:Incidence, risk factors, and outcomes of osteonecrosis of the jaw:integrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastases. Ann Oncol 23:1341-1347, 2012
16) Yoneda T, Hagino H, Sugimoto T et al:Bisphosphonate-related osteonecrosis of the jaw:Position paper from the allied task force committee of Japanese society for bone and mineral research, Japan osteoporosis society, Japanese society of periodontology, Japanese society for oral and maxillofacial radiology and Japanese society of oral and maxillofacial surgeons. J Bone Miner Metab:in press, 2010
17) Yang SP, Kim TW, Boland PJ et al:Retrospective review of atypical femoral fracture in metastatic bone disease patients receiving denosumab therapy. Oncologist 22:438-444, 2017
18) Lockwood M, Banderudrappagari R, Suva LJ et al:Atypical femoral fractures from bisphosphonate in cancer patients - Review. J Bone Oncol 18:100259, 2019
19) Awan AA, Hutton B, Hilton J et al:De-escalation of bone-modifying agents in patients with bone metastases from breast cancer:a systematic review and meta-analysis. Breast Cancer Res Treat 176(3):507-517, 2019
20) Clemons M, Ong M, Stober C et al:A randomised trial of 4- versus 12-weekly administration of bone-targeted agents in patients with bone metastases from breast or castration-resistant prostate cancer. Eur J Cancer 142:132-140, 2021
P.275 掲載の参考文献
1) Rich SE, Chow R, Raman S et al:Update of the systematic review of palliative radiation therapy fractionation for bone metastases. Radiother Oncol 126(3):547-557, 2018
2) Donovan EK, Sienna J, Mitera G et al:Single versus multifraction radiotherapy for spinal cord compression:A systematic review and meta-analysis. Radiother Oncol 134:55-66, 2019
3) Cox BW, Spratt DE, Lovelock M et al:International Spine Radiosurgery Consortium consensus guidelines for target volume definition in spinal stereotactic radiosurgery. Int J Radiat Oncol Biol Phys 83(5):e597-605, 2012
4) Ryu S, Deshmukh S, Timmerman RD et al:Radiosurgery compared to external beam radiotherapy for localized spine metastasis:Phase III Results of NRG Oncology/RTOG 0631. Int J Radiat Oncol Biol Phys 105(1s):S2-3, 2019
5) Sahgal A, Myrehaug SD, Siva S et al:CCTG SC.24/TROG 17.06:A randomized phase II/III study comparing 24 Gy in 2 stereotactic body radiotherapy(SBRT) fractions versus 20 Gy in 5 conventional palliative radiotherapy(CRT) fractions for patients with painful spinal metastases. Int J Radiat Oncol Biol Phys 108(5):1397-1398, 2020
P.284 掲載の参考文献
1) Kobayashi T, Arai Y, Takeuchi Y et al:Phase I/II clinical study of percutaneous vertebroplasty(PVP) as palliation for painful malignant vertebral compression fractures(PMVCF):JIVROSG-0202. Ann Oncol 20:1943-1947, 2009
2) Saravana-Bawan S, David E et al:Palliation of bone metastases-exploring options beyond radiotherapy. Ann Palliat Med 8:168-177, 2019
3) Chiras J, Shotar E, Cormier E et al:Interventional radiology in bone metastases. Eur J Cancer Care 26, 2017(Epub 2017 Sep 5)
4) Tanigawa N, Arai Y, Yamakado K et al:Phase I/II study of radiofrequency ablation for painful bone metastases:Japan Interventional Radiology in Oncology Study Group 0208. Cardiovasc Intervent Radiol 41:1043-1048, 2018
5) Chiras J, Adem C, Vallee J et al:Selective intra-arterial chemoembolization of pelvic and spine bone metastases. Eur Radiol 14:1774-1780, 2004
6) Koike Y, Takizawa K, Ogawa Y et al:Transcatheter arterial chemoembolization (TACE) or embolization(TAE) for symptomatic bone metastases as a palliative treatment. Cardiovasc Intervent Radiol 34:793-801, 2011
7) https://www.jsir.or.jp/about/hospital/
P.297 掲載の参考文献
1) 大島和也:脊椎転移外科的治療のタイミング. "がん患者の運動器疾患の診かた 新たなアプローチ「がんロコモ」"森岡秀夫, 河野博隆 編. 中外医学社, 102-114, 2019
2) 大島和也:【がん患者の運動器マネージメント-がんロコモとは-】がんとロコモティブシンドローム(がんロコモ)のニューフロンティア-入院から在宅へ」のいま, 求められる医療者の役割とは?- 運動器リハ 30(3):276-284, 2019
3) 大島和也:【がんロコモの展望】がん患者に対する手術介入によるQOL 改善の実際. 整外と災外 62(7):843-849, 2019
4) 大島和也, 荒木信人:脊椎転移と脊髄麻痺. "癌と骨"松本俊夫, 米田俊之 編. メディカルレビュー社, 159-172, 2013
5) 大島和也:脊椎転移のトータルケア. "脊椎転移パーフェクト診療 がんロコモを防ぐために"高木辰哉 編. 南江堂, 124-131, 2020
6) 大島和也:がん診療X整形外科「がんロコモ」 がん診療において『動ける』ことの意義とは? 臨整外 54(10):1001-1005, 2019
7) 大島和也, 吉川秀樹:「動ける」ことを意識した骨転移診療の意義. "整形外科医が今日から始める がんロコモ". ロコモチャレンジ!推進協議会 がんロコモワーキンググループ 編. 総合医学社, 144-151, 2019
P.306 掲載の参考文献
1) Mirels H:Metastatic disease in long bones:a proposed scoring system for diagnosing impending pathologic fractures. Clin Orthop 249:256-264, 1989
2) 日本臨床腫瘍学会 編:骨転移診療ガイドライン. 南江堂, 2016
3) Wachenfeld I, Sanner G, Bottcher HD et al:The remineralization of the vertebral metastases of breast carcinoma after radiotherapy. Strahlenther Onkol 172:332-341, 1996
4) Abouarab MH, Salem IL, Degheidy MM et al:Therapeutic options and postoperative wound complications after extremity soft tissue sarcoma resection and postoperative external beam radiotherapy. Int Wound J 15:148-158, 2018
P.313 掲載の参考文献
1) 日本臨床腫瘍学会 編:骨転移診療ガイドライン. 南江堂, pp22-23, 2015
2) 日本リハビリテーション医学会, がんのリハビリテーションガイドライン策定委員会編:がんのリハビリテーション診療ガイドライン第2版, pp176-178, 金原出版, 2019
3) Fisher CG et al:A novel classification system for spinal instability in neoplastic disease:an evidence-based approach and expert consensus from the Spine Oncology Study Group. Spine(Phila Pa 1976) 35:E1221-1229, 2010
4) Van der Linden YM et al:Comparative analysis of risk factors for pathological fracture with femoral metastases. J Bone Joint Surg Br 86:566-573, 2004
5) Y Shinoda et al:Prediction of pathological fracture in patients with lower limb bone metastasis using computed tomography imaging. Clin Exp Metastasis 37(5), 2020
P.319 掲載の参考文献
1) 酒井良忠:高齢者の骨転移のリハビリテーション治療. MEDICAL REHABILITATION 255:39-44, 2020
2) 日本臨床腫瘍学会 編:骨転移診療ガイドライン. 南江堂, 52-23, 2015
3) 日本リハビリテーション医学会 編:がんのリハビリテーション診療ガイドライン 第2版. 金原出版, 172-175, 2019
4) Fisher CG et al:A novel classification system for spinal instability in neoplastic disease:an evidence-based approach and expert consensus from the Spine Oncology Study Group. Spine(Phila Pa 1976) 35(22):E1221-E1229, 2010
5) Mirels H:Metastatic disease in long bone. A proposed scoring system for diagnosing impending pathologic fractures. Clin Orthop Relat Res 249:256-264, 1989
P.327 掲載の参考文献
1) 国立がん研究センターがん情報サービスホームページより「がん登録・統計」 https://ganjoho.jp/reg_stat/
2) Kaasa S, Brenne E, Lund JA et al:Prospective randomised multicenter trial on single fraction radiotherapy(8 Gy x1) versus multiple fractions(3 Gy x10) in the treatment of painful bone metastases. Radiother Oncol 79(3):278-84, 2006
3) 笹井啓資:放射線治療. 大森まいこ他 編, 骨転移の診療とリハビリテーション. 医歯薬出版, 30-34, 2014
4) 大森まいこ:リハビリテーション目標, リスク管理の実際. 大森まいこ他 編, 骨転移の診療とリハビリテーション. 医歯薬出版, 92-106, 2014
P.336 掲載の参考文献
1) 厚生労働省:がん診療連携拠点病院の整備に関する指針. 健発第0301001号厚生労働省健康局長通知. 2008
2) 日本臨床腫瘍学会 編:骨転移診療ガイドライン. 南江堂, 2015
3) 眞鍋 淳:がん骨転移に対する集学的治療-骨転移Cancer Board とBone Management-. 癌の臨床 58:43-50, 2012
4) 眞鍋 淳:骨転移に対する診断と治療-Cancer Board による集学的チーム医療について-. 癌と化学療法 37:211-216, 2010
5) Vieillard MH, Thureau S:Multidisciplinary meetings dedicated to bone metastases:a historical perspective and rationale. Bull Cancer 100(11):1135-1139, 2013
6) Kimura T:Multidisciplinary approach for bone metastasis:A review. Cancers(Basel) 10(6):156, 2018
7) Ibrahim T, Flamini E, Fabbri L et al:Multidisciplinary approach to the treatment of bone metastases:Osteo-Oncology Center, a new organizational model. Tumori. 95 (3):291-297, 2009
8) 佐藤信吾, 大川 淳:大学病院でのがん診療に求められる運動器マネジメント. 「整形外科医が今日から始めるがんロコモ」. 総合医学社, 90-99, 2019
9) 佐藤信吾:ひとりじゃない, チームで行う骨転移診療. Bone Joint Nerve 10(3):397-403, 2020
10) 佐藤信吾:骨転移キャンサーボード-立ち上げから運営まで-. 「がん患者の運動器疾患の診かた-新たなアプローチ「がんロコモ」-」. 中外医学社, 216-222, 2019
P.345 掲載の参考文献
1) 城戸 顕, 石田由佳子:脊椎転移の至適介入について. "脊椎転移パーフェクト診療-がんロコモを防ぐために-"高木辰哉 編. 南江堂, 118-123, 2020
2) 石田由佳子, 塚本真治, 重松英樹 他:骨転移キャンサーボードにおけるチームマネージメント. Journal of Clinical Rehabilitation 30:27-32, 2021
3) Yamanaka N, Tsukamoto S, Ishida Y et al:Clinical questions on rehabilitation in cancer patients with skeletal metastasis:a content analysis of the multidisciplinary tumor board records. Support Care Cancer, 2020 Aug 25. doi:10.1007/s00520-020-05696-3
4) Fisher CG, DiPaola CP, Ryken TC et al:A novel classification system for spinal instability in neoplastic disease:an evidence-based approach and expert consensus from the Spine Oncology Study Group. Spine 35:1221-1229, 2010
5) 田中誠人, 重松英樹, 宮坂俊輝 他:転移性脊椎腫瘍の早期発見・介入をめざす院内CT・MRI画像診断との連携システムの試み. 整形外科 68:1147-1150, 2017
P.352 掲載の参考文献
1) Manger B, Schett G:Paraneoplastic syndromes in rheumatology. Nat Rev Rheumatol 10:662-670, 2014
2) Morel J, Deschamps V, Toussirot E et al:Characteristics and survival of 26 patients with paraneoplastic arthritis. Ann Rheum Dis 67:244-247, 2008
3) Pineda C, Martinez-Lavin M:Hypertrophic osteoarthropathy:what a rheumatologist should know about this uncommon condition. Rheum Dis Clin North Am 39:383-400, 2013
4) Manger B, Schett G:Palmar fasciitis and polyarthritis syndrome-systematic literature review of 100 cases. Semin Arthritis Rheum 44:105-111, 2014
5) Minisola S, Peacock M, Fukumoto S et al:Tumour-induced osteomalacia. Nat Rev Dis Primers 3:17044, 2017
6) Van Thillo A, Vulsteke JB, Van Assche D et al:Physical therapy in adult inflammatory myopathy patients:a systematic review. Clin Rheumatol 38:2039-2051, 2019
7) Richter MD, Crowson C, Kottschade LA et al:Rheumatic syndromes associated with immune checkpoint inhibitors:A single-center cohort of sixty-one patients. Arthritis Rheumatol 71:468-475, 2019
8) Singer O, Cigler T, Moore AB et al:Defining the aromatase inhibitor musculoskeletal syndrome:a prospective study. Arthritis Care Res(Hoboken) 64:1910-1918, 2012
P.358 掲載の参考文献
1) Tokuda Y, Maezato K, Stein GH:The causes of hypercalcemia in Okinawan patients:an international comparison. Intern Med 46(1):23-28, 2007
2) Stewart AF:Clinical practice. Hypercalcemia associated with cancer. N Engl J Med 352(4):373-379, 2005
3) Nelson KA, Walsh D, Abdullah O et al:Common complications of advanced cancer. Semin Oncol 27(1):34-44, 2000
4) Major P, Lortholary A, Hon J et al:Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy:a pooled analysis of two randomized, controlled clinical trials. J Clin Oncol 19(2):558-567, 2001
5) Hu MI, Glezerman IG, Leboulleux S et al:Denosumab for treatment of hypercalcemia of malignancy. J Clin Endocrinol Metab 99(9):3144-3152, 2014
P.362 掲載の参考文献
1) Seretny M et al:Incidence, prevalence, and predictors of chemotherapy-induced peripheral neuropathy:A systematic review and meta-analysis. Pain 155:2461-70, 2014
2) Hou S et al:Treatment of chemotherapy-induced peripheral neuropathy:Systematic review and recommendations. Pain Physician 21:571-592, 2018
3) がんサポーティブケア学会 編:"がん薬物療法に伴う末梢神経障害マネジメントの手引き2017年版". 金原出版, p13, 2017
4) Sluka KA et al:Regular physical activity prevents development of chronic pain and activation of central neurons. J Appl Physiol 114:725-733, 2013
5) Kami K et al:Exercise-induced hypoalgesia:potential mechanism in animal models of neuropathic pain. Anat Sci Int 92:79-90, 2017
6) Kleckner IR et al:Effects of exercise during chemotherapy on chemotherapy-induced peripheral neuropathy:a multicenter, randomized controlled trial. Support Care Cancer 26:1019-1028, 2018
7) Andersen Hammond E et al:An exploratory randomized trial of physical therapy for the treatment of chemotherapy-induced peripheral neuropathy. Neurorehabil Neural Repair 34:235-246, 2020
P.370 掲載の参考文献
1) Davis MP, Panikkar R:Sarcopenia associated with chemotherapy and targeted aegnts for cancer therapy. Ann Palliat Med 8(1):86-101, 2019
2) Ferdandes R, Massarello S, Hutton B et al:Taxane acute pain syndrome(TAPS) in patients receiving taxane-based chemotherapy for breast cancer-a systematic review. Support Care Cancer 24:3633-3650, 2016
3) Cappelli LC, Gutierrez AK, Bingham CO 3rd, et al:Rheumatic and musculoskeletal immune-related adverse events due to immune checkpoint inhibitors:A systematic review of the literature. Arthritis Care Res(Hoboken) 69(11):1751, 2017
4) Desai J, Yassa L, Marqusee E et al:Hypothyroidism after sunitinib treatment for patients with gastrointestinal stromal tumors. Ann Intern Med 145(9):660, 2006
5) Wacker A, Lersch C, Scherpinski U et al:High incidence of angina pectoris in patients treated with 5-fluorouracil. A planned surveillance study with 102 patients. Oncology 65(2):108, 2003
P.466 掲載の参考文献
1) 国立がん研究センターがん情報サービス「2020年のがん統計予測」 https://ganjoho.jp/reg_stat/statistics/stat/short_pred.html
2) National Lung Screening Trial Research Team;Denis RA, Adams AM, Berg CD et al:Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med 365:395-409, 2011
3) Hess KR, Varadhachary GR, Taylor SH et al:Metastatic patterns in adenocarcinoma. Cancer 106:1624-1633, 2006
4) Katakami N, Kunikane H, Takeda K et al:Prospective study on the incidence of bone metastasis(BM) and skeletal-related events(SREs) in patients(pts) with stage IIIB and IV lung cancer-CSP-HOR 13. J Thorac Oncol 9:231-238, 2014
5) Bauml J, Mick R, Zhang Y et al:Determinants of survival in advanced non--small-cell lung cancer in the era of targeted therapies. Clin Lung Cancer 14:581-591, 2013
6) Daichi F, Ueda H, Shimizu R et al:Features and prognostic impact of distant metastasis in patients with stage IV lung adenocarcinoma harboring EGFR mutations:importance of bone metastasis. Clin Exp Metastasis 31:543-551, 2014
7) Landi L, D'Inca F, Gelibter A et al:Bone metastases and immunotherapy in patients with advanced non-small-cell lung cancer. J Immunother Cancer 7:316, 2019
8) Li X, Wang L, Chen S et al:Adverse impact of bone metastases on clinical outcomes of patients with advanced non-small cell lung cancer treated with immune checkpoint inhibitors. Thorac Cancer 11:2812-2819, 2020
9) Sekine I, Nokihara H, Yamamoto N et al:Risk factors for skeletal-related events in patients with non-small cell lung cancer treated by chemotherapy. Lung Cancer 65:219-222, 2009
10) Rosen LS, Gordon D, Tchekmedyian NS et al:Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors:a randomized, Phase III, double-blind, placebo-controlled trial. Cancer 100:2613-2621, 2004
11) Henry DH, Costa L, Goldwasser F et al:Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer( excluding breast and prostate cancer) or multiple myeloma. J Clin Oncol 29:1125-1132, 2011
12) Scagliotti GV, Hirsh V, Siena S et al:Overall survival improvement in patients with lung cancer and bone metastases treated with denosumab versus zoledronic acid:subgroup analysis from a randomized phase 3 study. JThorac Oncol 7:1823-1829, 2012
13) Cui X, Li S, Gu J et al:Retrospective study on the efficacy of bisphosphonates in tyrosine kinase inhibitor-treated patients with non-small cell lung cancer exhibiting bone metastasis. Oncol Lett 18:5437-5447, 2019
14) Peters S, Danson S, Hasan B et al:A randomized open-label phase III trial evaluating the addition of Denosumab to standard first-line treatment in advanced NSCLC:The European Thoracic Oncology Platform(ETOP) and European Organisation for Research and Treatment of Cancer(EORTC) SPLENDOUR Trial. J Thorac Oncol 15:1647-1656, 2020
P.490 掲載の参考文献
1) 甲状腺腫瘍診療ガイドライン作成委員会:甲状腺腫瘍診療ガイドライン2018. 日内分泌・甲状腺外会誌35 増刊号:12, 2018
2) 日本内分泌外科学会・日本甲状腺病理学会 編:甲状腺癌取扱い規約 第8版. 金原出版, 12-22, 2019
3) 甲状腺腫瘍診療ガイドライン作成委員会:甲状腺腫瘍診療ガイドライン2018. 日内分泌・甲状腺外会誌35 増刊号:10-11, 2018
4) Higashiyama T, Ito Y, Hirokawa M et al:Induction chemotheraphy with weekly paclitaxel administration for anaplastic thyroid carcinoma. Thyroid 20:7-14, 2010
5) Hesselink ENK, Hesselink MSK, de Bock GH et al:Long-term cardiovascular mortality in patients with differentiated thyroid carcinoma:an observational study. J Clin Oncol 31:4046-4053, 2013
6) 日本臨床腫瘍学会 編:骨転移診療ガイドライン. 南江堂, 2, 2015
7) Muresan MM, Olivier P, Sirveaus F et al:Bone metastases from differentiated thyroid carcinoma. Endocrine-Related Cancer 15:37-49, 2008
8) Osorio M, Moubayed SP, Su H et al:Systematic review of site distribution of bone metastases in differentiated thyroid cancer. Head and Neck Surgery 39:812-818, 2017
9) Petrich T, Widjaja A, Musholt TJ et al:Outcome after radioiodine therapy in 107 patients with differentiated thyroid carcinoma and initial bone metastases. Eur J Nucl Med 28:203-208, 2001
P.498 掲載の参考文献
1) Tanaka F, Yamamoto K, Suzuki S et al:Strong interaction between the effects of alcohol consumption and smoking on oesophageal squamous cell carcinoma among individuals with ADH1B and/or ALDH2 risk alleles. Gut 59:1457-1464, 2010
2) 日本食道学会 編:食道癌診療ガイドライン2017年版. 金原出版, 2017
3) Kakeji Y, Takahashi A, Hasegawa H et al:Surgical outcomes in gastroenterological surgery in Japan:Report of the National Clinical Database 2011-2018. Ann Gastroenterol Surg 4(3):250-274, 2020
4) 日本胃癌学会 編:胃癌治療ガイドライン第5版. 金原出版
5) 国立がん研究センターがん情報サービス
6) 日本食道学会 編:Comprehensive registry of esophageal cancer in Japan. 2013
7) Nakamura K, Tomioku M, Nabeshima K et al:Clinicopathologic features and clinical outcomes of gastric cancer patients with bone metastasis. Tokai J Exp Clin Med 39 (4):193-198, 2014
P.504 掲載の参考文献
1) 大腸癌研究会 編:大腸癌治療ガイドライン医師用2019年版. 金原出版, 2019
2) Guan Xu, Ma CX, Quan JC et al:A clinical model to predict the risk of synchronous bone metastasis in newly diagnosed colorectal cancer:a population-based study. BMC Cancer 19:704, 2019
3) 日本臨床腫瘍学会 編:骨転移診療ガイドライン. 南江堂, 2015
4) Kawamura H, Yamaguchi Y, Yano Y et al:Characteristics and prognostic factors of bone metastasis in patients with colorectal cancer. Dis Colon Rectum 61:673-678, 2018
P.513 掲載の参考文献
1) 日本肝臓学会:肝癌診療ガイドライン2017年度版. 金原出版, 2017
2) 日本肝癌研究会:原発性肝癌取扱い規約 第6版補訂版. 金原出版, 2019
3) Kudo M et al:Lenvatinib as an initial treatment in patients with intermediate-stage hepatocellular carcinoma beyond up-to-seven criteria and child-pugh a liver function:A proof-of-concept study. Cancers(Basel) 11(8):1084, 2019
4) Kim S et al:Bone metastasis from primary hepatocellular carcinoma:characteristics of soft tissue formation. Cancer Res Treat 39(3):104-108, 2007
P.519 掲載の参考文献
1) Kimata Y et al:Postoperative complications and functional results after total glossectomy with microvascular reconstruction. Plast Reconstr Surg 106:1028-1035, 2000
2) D'Cruz AK et al:Elective versus therapeutic neck dissection in node-negative oral cancer. N Engl J Med 373:521-529, 2015
3) 辻 哲也 他:頸部郭清術の周術期リハビリテーション. 多職種チームのための周術期マニュアル4 頭頸部癌(鬼塚哲郎 編). メヂカルフレンド社, 276-298, 2006
4) Elting LS et al:The burdens of cancer therapy. Clinical and economic outcomes of chemotherapy-induced mucositis. Cancer 98(7):1531-1539, 2003
5) Dennis F et al:Final results of the 94-01 French head and neck oncology and radiotherapy group randomized trial comparing radiotherapy alone with concomitant radiochemotherapy in advanced stage oropharynx carcinoma. J Chin Oncol 22:69-76, 2004
6) Teo PM et al:Prognosticators determing survival subsequent to distant metastasis from nasopharyngeal carcinoma. Cancer 77:2423-2431, 1996
7) Grisanti S et al:Bone metastases from head and neck malignancies:Prognostic factors and skeletal-related events. PLoS ONE 14(3):e0213934, 2019

最近チェックした商品履歴

Loading...